LA JOLLA PHARMACEUTICAL COMPANY Corporate Presentation
March 2022
Forward-looking Statements
This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA (angiotensin II) and XERAVA (eravacycline) sales; operating costs; regulatory actions relating to La Jolla's products by the U.S. Food and Drug Administration (FDA), European Commission, China National Medical Products Administration and/or other regulatory authorities; expected future cash flows of La Jolla, including upfront, milestone, royalty and other payments resulting from La Jolla's out-license agreements and commercial supply agreements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
2
Our Mission
La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases
3
Product Portfolio
Product | Indication | Pivotal Studiesa | Regulatory Status |
GIAPREZA® | Septic or other | 321-patient, multinational, | FDA-approved Dec 2017 |
distributive | double-blind, randomized, | ||
(angiotensin II) | European Commission- | ||
shockb | placebo-controlled study | ||
approved Aug 2019 | |||
538-patient, multinational, | FDA-approved Aug 2018 | ||
Complicated | double-blind, randomized, | ||
XERAVA® | active-controlled study | European Commission- | |
intra-abdominal | approved Sep 2018 | ||
(eravacycline) | 499-patient, multinational, | ||
infectionsc | |||
double-blind, randomized, | NDA submitted in China | ||
active-controlled study | Mar 2021 |
- For U.S. and European approval
-
U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock
European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies - U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAIs) in patients 18 years of age and older
European Union: XERAVA is indicated for the treatment of cIAI in adults
4
GIAPREZA is a vasoconstrictor to increase
blood pressure in adults with septic or
other distributive shock
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
La Jolla Pharmaceutical Company published this content on 17 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 March 2022 00:50:04 UTC.
